Form 4: Wellington Biomedical Innovation Reports Conversion of Preferred Stock to Common Stock in MBX Biosciences, Inc.

Wellington Biomedical Innovation Master Investors (Cayman) II L.P. reports the conversion of Series B and Series C Preferred Stock to Common Stock in MBX Biosciences, Inc. upon the closing of the Issuer's initial public offering.

Summary

• On September 16, 2024, Wellington Biomedical Innovation Master Investors (Cayman) II L.P. reported the conversion of its Series B and Series C Preferred Stock into Common Stock of MBX Biosciences, Inc.
• The conversions occurred immediately prior to the closing of MBX Biosciences' initial public offering (IPO).
• 16,666,666 shares of Series B Preferred Stock were converted into 1,386,335 shares of Common Stock at a conversion ratio of 12.0221-for-one.
• 4,854,368 shares of Series C Preferred Stock were converted into 403,787 shares of Common Stock at a conversion ratio of 12.0221-for-one.
• Following the reported transactions, Wellington Biomedical Innovation Master Investors (Cayman) II L.P. directly owns 1,790,122 shares of MBX Biosciences, Inc. Common Stock.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a standard conversion of preferred stock to common stock following an IPO. The IPO itself is generally a positive event, hence the slightly positive sentiment.

Positives

• The conversion of preferred stock to common stock typically simplifies the capital structure of the company.
• The IPO likely provided capital for future growth.

Future Outlook

The document does not contain specific forward-looking statements regarding MBX Biosciences' future performance.

Industry Context

This filing is a standard SEC Form 4, reflecting changes in beneficial ownership following a corporate event (the IPO). It's common for preferred stock held by early investors to convert to common stock upon an IPO.

Stakeholder Impact

• The conversion of preferred stock to common stock may dilute existing shareholders' ownership.

Key Dates